Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - non-small


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8503
Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

David J. Kwiatkowski · Valerie W. Rusch · Jamie E. Chaft · Bruce E. Johnson · Alan Nicholas · Ignacio Ivan Wistuba · Robert E. Merritt · Jay M. Lee · Paul A. Bunn · Yan Tang · See-Chun Phan · Saiama N. Waqar · Alexander Patterson · Eric B. Haura · Eric M. Toloza · Karen L. Reckamp · Dan J. Raz · Katja Schulze · Ann M. Johnson · David P. Carbone ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9000
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

Kazuhiko Nakagawa · Edward B. Garon · Takashi Seto · Makoto Nishio · Santiago Ponce Aix · Chao-Hua Chiu · Keunchil Park · Silvia Novello · Ernest Nadal · Fumio Imamura · Kiyotaka Yoh · Jin-Yuan Shih · Kwok Hung Au · Denis Moro-Sibilot · Sotaro Enatsu · Annamaria Zimmermann · Bente Frimodt-Moller · Carla M. Visseren Grul · Martin Reck ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS3162
A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer.

Patrick Schöffski · Philippe Aftimos · Christophe Massard · Antoine Italiano · Christiane Jungels · Karen Andreas · Mitchell Keegan · Peter T.C. Ho ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9017
Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC).

Lingzhi Hong · Seyedeh Dibaj · Marcelo Vailati Negrao · Alexandre Reuben · Emily Roarty · Waree Rinsurongkawong · Jeffrey A. Lewis · Don Lynn Gibbons · Boris Sepesi · Vassiliki A Papadimitrakopoulou · Bonnie S. Glisson · George R. Blumenschein · Phillip Andrew Futreal · Ignacio Ivan Wistuba · Jack A. Roth · Stephen G. Swisher · John Victor Heymach · George R. Simon · Jiun-Kae Jack Lee · Jianjun Zhang ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8511
Prospective phase I multi-institutional trial of PD-1 blockade with pembrolizumab during concurrent chemoradiation for locally advanced, unresectable non-small cell lung cancer.

Salma K. Jabbour · Abigail T. Berman · Roy H. Decker · Yong Lin · Steven J. Feigenberg · Scott N. Gettinger · Charu Aggarwal · Corey J. Langer · Charles B. Simone · Jeffrey D. Bradley · Joseph Aisner · Jyoti Malhotra ·

Medicine
PDF

Background We aimed to assess the role of genomic HLA-I/II heterozygosity in the overall survival benefit in patients with unresectable locally advanced, metastatic non-small lung cancer treated by PD1/L1 inhibitors.

Genomic HLA heterozygosity as a predictive marker for survival in lung cancer patients post immunotherapy [10.1093/annonc/mdz446.013]


Subsequent studies showed that CA-5f exhibited strong cytotoxicity against A549 non-small cell lung cancer (NSCLC) cells, but low cytotoxicity to normal human umbilical vein endothelial cells (HUVECs), by increasing mitochondrial-derived reactive oxygen species (ROS) production.

Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer [10.1080/15548627.2018.1511503]


The current study evaluates reliability, clinical relevance, and large-scale feasibility for a previously documented method with which to characterize cancer progression outcomes in advanced non–small-cell lung cancer from electronic health record (EHR) data.

Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set [10.1200/CCI.19.00013]


OR Non-Small-Cell Lung Carcinomas [Title/] OR Nonsmall Cell Lung Cancer [Title/] OR Non-Small-Cell Lung Carcinoma [Title/] OR Non Small Cell Lung Carcinoma [Title/] OR Carcinoma, Non-Small Cell Lung [Title/] OR Non-Small Cell Lung Cancer [Title/] OR “Carcinoma, NonSmall-Cell Lung” [Mesh] AND placebo [Title/]) OR “Controlled Clinical Trial” [Publication Type] OR “Randomized Controlled Trial” [Publication Type].

Postoperative UFT-/Tegafur-based Chemotherapy Versus Postoperative Radiotherapy for Early-stage Non-small Cell Lung Cancer:A Systematic Review and Network Meta-analysis [10.30564/jor.v1i2.1493]


SummaryPurpose We investigated the safety, tolerability, pharmacokinetics, and efficacy of TAS-121, a novel, potent, and highly selective third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in Japanese patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) previously treated with EGFR-TKI.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations [10.1007/s10637-019-00732-4]


Highly Related Keywords from non-small

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals